| 1 |
International Agency for Research on Cancer. Global Cancer Observatory: Cancer Today [EB/OL]. [2021-01-11].
URL
|
| 2 |
Sasaki Y, Tsuda H. Clinicopathological characteristics of triple-negative breast cancers [J]. Breast Cancer, 2009, 16(4): 254-259.
|
| 3 |
Rhee J, Han SW, Oh DY, et al. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer [J]. BMC Cancer, 2008, 8(1): 307.
|
| 4 |
Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence [J]. Clin Cancer Res, 2007, 13(15): 4429-4434.
|
| 5 |
Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer [J]. N Engl J Med, 2009, 353(16): 1673-1684.
|
| 6 |
Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100000 women in 123 randomised trials [J]. The Lancet, 2012, 379(9814): 432-444.
|
| 7 |
Zhang X, Claerhout S, Prat A, et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models [J]. Cancer Research, 2013, 73(15): 4885-4897.
|
| 8 |
Manoir SD, Orsetti B, Rui BG, et al. Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse [J]. Mol Oncol, 2014, 8(2): 431-443.
|
| 9 |
Ledford H. US cancer institute to overhaul tumour cell lines [J]. Nature, 2016, 530(7591): 391-391.
|
| 10 |
Gómez-Miragaya J, Palafox M, Paré L, et al. Resistance to taxanes in triple-negative breast cancer associates with the dynamics of a CD49f+ tumor-initiating population [J]. Stem Cell Reports, 2017, 8(5): 1392-1407.
|
| 11 |
Kagan HM, Li W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell [J]. J Cell Biochem, 2003, 88(4): 660.
|
| 12 |
Saatci O, Kaymak A, Raza U, et al. Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer [J]. Nat Commun, 2020, 11(1): 2416.
|
| 13 |
Marty B, Maire V, Gravier E, et al. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells [J]. Breast Cancer Res, 2008, 10(6): R101.
|
| 14 |
Zeng Q, Yang Z, Gao YJ, et al. Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study [J]. Eur J Cancer, 2010, 46(6): 1132-1143.
|
| 15 |
Zhang H, Cohen AL, Krishnakumar S, et al. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition [J]. Breast Cancer Res, 2014, 16(2): R36.
|
| 16 |
Marangoni E, Laurent C, Coussy F, et al. Capecitabine efficacy is correlated with TYMP and RB expression in PDX established from triple-negative breast cancers [J]. Clin Cancer Res, 2018, 24(11): 2605-2615.
|
| 17 |
Cowan LA, Talwar S, Yang AS. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors [J]. Epigenomics, 2010, 2(1): 71-86.
|
| 18 |
Jia Y, Bo Q, Moyer AM, et al. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine [J]. J Clin Invest, 2018, 128(6): 2376-2388.
|
| 19 |
Dang C. MYC on the path to cancer [J]. Cell, 2012, 149(1): 22-35.
|
| 20 |
Dai H, Kusdra L, Huskey NE, et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition [J]. J Exp Med, 2012, 209(4): 679-696.
|
| 21 |
Dai H, Camarda R, Zhou AY, et al. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression [J]. Nat Med, 2016, 22(11): 1321-1329.
|
| 22 |
Liu Y, Zhou Y, Huang KH, et al. Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor [J]. Cell Prolif, 2020, 53(8): e12858.
|
| 23 |
Contrino J, Hair G, Kreutzer DL, et al. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease [J]. Nat Med, 1996, 2(2): 209-215.
|
| 24 |
Duanmu J, Cheng J, Xu J, et al. Effective treatment of chemoresistant breast cancer in vitro and in vivo by a factor Ⅷ-targeted photodynamic therapy [J]. Br J Cancer, 2011, 104(9): 1401-1409.
|
| 25 |
Hu Z, Shen R, Campbell A, et al. Targeting tissue factor for immunotherapy of triple-negative breast cancer using a second-generation ICON [J]. Cancer Immunol Res, 2018, 6(6): 671-684.
|
| 26 |
Bourcy M, Suarez-Carmona M, Lambert J, et al. Tissue factor induced by epithelial-mesenchymal transition triggers a pro-coagulant state that drives metastasis of circulating tumor cells [J]. Cancer Res, 2016, 76(14): 4270-4282.
|
| 27 |
Bousquet G, Feugeas JP, Ferreira I, et al. Individual xenograft as a personalized therapeutic resort for women with metastatic triple-negative breast carcinoma [J]. Breast Cancer Res, 2014, 16(1): 401-403.
|
| 28 |
Moon HG, Oh K, Lee J, et al. Prognostic and functional importance of the engraftment-associated genes in the patient-derived xenograft models of triple-negative breast cancers [J]. Breast Cancer Res Treat, 2015, 154(1): 13-22.
|
| 29 |
Peterson JK, Houghton PJ. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development [J]. Eur J Cancer, 2004, 40(6): 837-844.
|
| 30 |
Izumchenko E, Paz K, Ciznadija D, et al. Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors [J]. Ann Oncol, 2017, 28(10): 2595-2605.
|